CSIMarket
 


Fulgent Genetics Inc   (FLGT)
Other Ticker:  
 
    Sector  Healthcare    Industry Medical Laboratories
   Industry Medical Laboratories
   Sector  Healthcare
 

FLGT's Capital Expenditures Growth by Quarter and Year

Fulgent Genetics Inc 's Capital Expenditures results by quarter and year




FLGT Capital Expenditures (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December - 4.72 6.02 23.79
III Quarter September 4.92 5.44 3.40 10.13
II Quarter June 12.14 3.26 2.94 0.41
I Quarter March 2.03 5.36 11.49 0.80
FY   19.09 18.78 23.85 35.13



FLGT Capital Expenditures third quarter 2023 Y/Y Growth Comment
Fulgent Genetics Inc reported decrease in Capital Expenditures in the third quarter 2023 by -9.5% to $ 4.92 millions, from the same quarter in 2022.
The decrease in the third quarter 2023 Fulgent Genetics Inc 's Capital Expenditures compares unfavorably to the Company's average Capital Expenditures doubling of 412.35%.

Looking into third quarter 2023 results within Medical Laboratories industry 4 other companies have achieved higher Capital Expenditures growth. While Fulgent Genetics Inc ' s Capital Expenditures decline of -9.5% ranks overall at the positon no. 626 in the third quarter 2023.




FLGT Capital Expenditures ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - -21.59 % -74.7 % 5071.74 %
III Quarter September -9.5 % 60 % -66.44 % 11155.56 %
II Quarter June 272.39 % 10.88 % 617.07 % -18 %
I Quarter March -62.13 % -53.35 % 1336.25 % 515.38 %
FY   - -21.26 % -32.11 % 2877.12 %

Financial Statements
Fulgent Genetics Inc 's third quarter 2023 Capital Expenditures $ 4.92 millions FLGT's Income Statement
Fulgent Genetics Inc 's third quarter 2022 Capital Expenditures $ 5.44 millions Quarterly FLGT's Income Statement
New: More FLGT's historic Capital Expenditures Growth >>


FLGT Capital Expenditures (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - -13.24 % 77.06 % 134.85 %
III Quarter September -59.45 % 66.87 % 15.65 % 2370.73 %
II Quarter June 498.03 % -39.18 % -74.41 % -48.75 %
I Quarter March -56.99 % -10.96 % -51.7 % 73.91 %
FY (Year on Year)   - -21.26 % -32.11 % 2877.12 %




Capital Expenditures third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #5
Healthcare Sector #78
Overall #626

Capital Expenditures Y/Y Growth Statistics
High Average Low
2872.08 % 412.35 % -74.73 %
(Dec 31 2020)   (Sep 30 2019)
Capital Expenditures third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #5
Healthcare Sector #78
Overall #626
Capital Expenditures Y/Y Growth Statistics
High Average Low
2872.08 % 412.35 % -74.73 %
(Dec 31 2020)   (Sep 30 2019)

Capital Expenditures by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Fulgent Genetics Inc 's Q/Q Capital Expenditures Growth


Capital Expenditures Q/Q Growth Statistics
High Average Low
2808.33 % 276.29 % -96.77 %
(Sep 30 2018)  


FLGT's III. Quarter Q/Q Capital Expenditures Comment
In the III. Quarter 2023 Fulgent Genetics Inc reported fall in Capital Expenditures sequentially by -59.45% to $ 4.92 millions, from $ 12.14 millions released in the previous reporting period.

Although cyclical factors commonly energize III. Quarter 2023 performance, this clearly was not substantial to recover FLGT's III. Quarter performance, Isaac R. Hill, a business researcher wrote.

Within Medical Laboratories industry 11 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Fulgent Genetics Inc 's Capital Expenditures growth quarter on quarter, overall rank is 1599.


Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #12
Healthcare Sector #216
Overall #1599
Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #12
Healthcare Sector #216
Overall #1599
Capital Expenditures Q/Q Growth Statistics
High Average Low
2808.33 % 276.29 % -96.77 %
(Sep 30 2018)  


FLGT's III. Quarter Q/Q Capital Expenditures Comment
In the III. Quarter 2023 Fulgent Genetics Inc reported fall in Capital Expenditures from the second quarter by -59.45% to $ 4.92 millions, from $ 12.14 millions declared a quarter before.

Even cyclical influence which commonly elevate III. Quarter 2023 results, it plainly was not substantial to salvage FLGT's III. Quarter outcome, Isaac R. Hill, a business researcher wrote.

Within Medical Laboratories industry 11 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Fulgent Genetics Inc 's Capital Expenditures growth quarter on quarter, overall rank is 1599.


Fulgent Genetics Inc 's 12 Months Capital Expenditures Growth Year on Year


Capital Expenditures TTM Growth

12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
12 Months Ending
(Sep 30 2022)
Cumulative Capital Expenditures 12 Months Ending $ 23.82 $ 24.34 $ 15.45 $ 18.78 $ 20.07
Y / Y Capital Expenditures Growth (TTM) 18.71 % 34.93 % -12.78 % -21.26 % -51.79 %
Year on Year Capital Expenditures Growth Overall Ranking # 1221 # 1879 # 987 # 1848 # 91
Seqeuential Capital Expenditures Change (TTM) -2.1 % 57.52 % -17.72 % -6.44 % 11.27 %
Seq. Capital Expenditures Growth (TTM) Overall Ranking # 626 # 1165 # 886 # 1928 # 1702




Cumulative Capital Expenditures growth Comment
With the quarterly Capital Expenditures reported in the Sep 30 2023 period, Fulgent Genetics Inc 's cumulative twelve months Capital Expenditures were $ 24 millions, company would post below average annual Capital Expenditures growth of 11.27% year on year, if the fiscal year would end at Sep 30 2023.
A slow-down in the Fulgent Genetics Inc 's Capital Expenditures growth from the 12.14% growth in Jun 30 2023.

In the Healthcare sector 171 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Total ranking has impoved so far to 1221, from total ranking in previous quarter at 1879.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
2872.08 %
412.35 %
-74.73 %
 

Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 5
Healthcare Sector # 172
Overall # 1221

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
2872.08 %
412.35 %
-74.73 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 5
Sector # 78
S&P 500 # 626
Cumulative Capital Expenditures growth Comment
With the quarterly Capital Expenditures reported in the Sep 30 2023 period, Fulgent Genetics Inc 's cumulative twelve months Capital Expenditures were $ 24 millions, company would post below average annual Capital Expenditures growth of -74.73% year on year, if the fiscal year would end at Sep 30 2023.
A slow-down in the Fulgent Genetics Inc 's Capital Expenditures growth from the 12.14% growth in Jun 30 2023.

In the Healthcare sector 171 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Total ranking has impoved so far to 1221, from total ranking in previous quarter at 1879.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
2872.08 %
412.35 %
-74.73 %
 


Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 5
Healthcare Sector # 172
Overall # 1221

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
2872.08 %
412.35 %
-74.73 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 5
Sector # 78
S&P 500 # 626




Other Capital Expenditures Growth
Medical Laboratories Industry Capital Expenditures Growth Trends and Statistics
Healthcare Sector Capital Expenditures Growth Statistics
Capital Expenditures Growth Trends for overall market
FLGT's Capital Expenditures Growth Ratio versus Medical Laboratories Industry, Healthcare Sector and total Market
Highest Ranking Capital Expenditures Growth
Lowest Ranking Capital Expenditures Growth
Capital Expenditures Growth for FLGT's Competitors
Capital Expenditures Growth for Fulgent Genetics Inc 's Suppliers
Capital Expenditures Growth for FLGT's Customers

You may also want to know
FLGT's Annual Growth Rates FLGT's Profitability Ratios FLGT's Asset Turnover Ratio FLGT's Dividend Growth
FLGT's Roe FLGT's Valuation Ratios FLGT's Financial Strength Ratios FLGT's Dividend Payout Ratio
FLGT's Roa FLGT's Inventory Turnover Ratio FLGT's Growth Rates FLGT's Dividend Comparisons



Companies with similar Capital Expenditures fall for the quarter ending Sep 30 2023 within Healthcare SectorY/Y Change %Capital Expenditures for the quarter ending Sep 30 2023
Encompass Health Corporation-0.54%$ -0.542 millions
Myriad Genetics Inc -1.13%$ -1.130 millions
Opgen inc -1.22%$ -1.220 millions
Avantor Inc -3.33%$ -3.333 millions
United Therapeutics Corporation-4.51%$ -4.506 millions
Enanta Pharmaceuticals Inc-4.80%$ -4.802 millions
Davita Inc -5.46%$ -5.463 millions
Science 37 Holdings Inc -5.63%$ -5.630 millions
Cutera Inc -5.71%$ -5.708 millions
Zoetis Inc -5.84%$ -5.844 millions
U S Physical Therapy Inc-6.25%$ -6.248 millions
Generation Bio Co -6.30%$ -6.298 millions
Ngm Biopharmaceuticals Inc -6.45%$ -6.452 millions
Becton Dickinson And Company-6.67%$ -6.667 millions
3m Company-6.90%$ -6.897 millions
Apyx Medical Corporation-7.45%$ -7.447 millions
Edwards Lifesciences Corporation-7.68%$ -7.679 millions
Viatris Inc -7.70%$ -7.700 millions
Luna Innovations Inc-8.23%$ -8.232 millions
Nevro Corp -8.38%$ -8.377 millions
Shockwave Medical Inc -8.65%$ -8.649 millions
Sonendo Inc -8.86%$ -8.861 millions
Charles River Laboratories International inc -8.90%$ -8.904 millions
Nautilus Biotechnology Inc -9.24%$ -9.242 millions
Harvard Bioscience Inc-9.28%$ -9.276 millions
Fulgent Genetics Inc -9.42%$ -9.420 millions
Idexx Laboratories Inc-9.53%$ -9.529 millions
Sage Therapeutics Inc -9.89%$ -9.890 millions
Caredx Inc -10.40%$ -10.400 millions
Quest Diagnostics Inc-11.02%$ -11.017 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com